Artificial intelligence companies often defy traditional valuation templates because their economics are shaped by recurring software revenue, proprietary data, model performance, compute intensity, and platform scalability. For investors and buyers, the central question is not just how much revenue an AI business generates today, but how durable that revenue is, how defensible the model is, […]
Electronic health record and health IT software companies are valued differently from traditional software businesses because their economics are shaped by recurring revenue, deep workflow integration, and high switching costs. For buyers and investors, the core question is not simply how much revenue a company generates, but how durable that revenue is, how efficiently it […]
AI-powered diagnostics companies are attracting significant attention from strategic acquirers, private equity groups, and health system buyers because they sit at the intersection of software, regulated medical technology, and data-driven clinical decision support. Their valuation is often driven less by current earnings alone and more by FDA clearance status, the durability of licensing revenue, the […]
Revenue cycle management (RCM) software companies occupy a unique place in business valuation because their economics are tied to embedded workflows, recurring revenue, and measurable reimbursement performance. For Philadelphia business owners, investors, and advisors, the key valuation question is not simply how much revenue an RCM company generates, but how durable that revenue is, how […]
Executive summary: Valuing a telehealth platform requires more than looking at revenue growth or headline patient volume. Buyers and investors focus on the relationship between visit volume, revenue per visit, payer contract penetration, retention, and the durability of demand after the pandemic surge. For Philadelphia business owners, especially those in healthcare and life sciences, understanding […]
Executive Summary: Healthtech companies are valued differently from traditional healthcare businesses because their economics often depend on recurring software revenue, user adoption, and evidence of clinical impact rather than only on historical earnings. For Philadelphia business owners, investors, and advisors evaluating a digital health company, the most important valuation drivers usually include annual recurring revenue […]
Executive Summary: InsurTech valuations depend on more than top-line growth. Investors and buyers focus on loss ratio, combined ratio, premium growth, retention, and the quality of embedded distribution because these metrics reveal whether a company can scale profitably and defensibly. For Philadelphia business owners, understanding how these indicators affect valuation is critical when raising capital, […]
Executive Summary. Buy Now, Pay Later, or BNPL, companies were once valued primarily on growth, user acquisition, and gross merchandise volume (GMV). That approach has changed. Today, buyers, lenders, and investors are focusing much more closely on unit economics, merchant fee rates, credit losses, and the path to sustainable profitability. For Philadelphia business owners, especially […]
Executive Summary: Neobank valuation is not based on the same framework used for a traditional bank. Investors still care about asset quality, capital strength, and earnings power, but challenger banks are usually priced more heavily on user economics, including deposits per customer, customer acquisition cost (CAC), revenue per account, retention, and the credibility of the […]
Executive Summary: Valuing a payment processing company requires a close look at the economics of every transaction the business touches. The most important drivers are total payment volume (TPV), take rate, gross margin, and churn, because together they determine how much revenue is converted into durable cash flow. Buyers typically value software-led payment businesses differently […]
- 1
- 2